A very good synopsis of this AM presentation by management.
To clarify on the 'partnering' it would only apply to AP534 in Japan and perhaps one or two other Asian countries. According to management assessment '113' will 'not' be partnered nor any other drugs that may be on the shelf. That brief exchange came from questioner inquiring about needing money again next year and wondering if Ariad would consider the '113' issue of partnering to help raise funds.
So i guess we shall, wait & see, wait & see, and wait & see. Or more of same, which ever comes first.
Then again, who knows. Maybe 'bellicum' or 'medinol' will surprise one day. Perhaps they will pull off a deal or two in Asia that may inspire.
With the recent hires, plus Mr Cole, and Mr Denner added to the franchise, they should certainly have enough 'brainpower' to do something constructive..
galt
